October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

Life science leaders with rounded corners lead to more enduring progress than razor-sharp perfection ever could, writes Tara ...

A major biopharmaceutical company faced equity and operational challenges from relying on temporary employees in long-term roles. These workers lacked full-time status and received limited, costly ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...